Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Swedish Orphan Biovitrum (BIOVF) had Revenue of $2.46B for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$2.46B
Net Income	$367.52M
Cost of Goods Sold	$547.26M
Gross Profit	$1.91B
Operating Expenses	$1.93B
Operating Income	$532.22M
Non-Operating Income/Expense	$-115.32M
Pre-Tax Income	$416.90M
Normalized Pre-Tax Income	$416.90M
Income after Taxes	$366.95M
Income from Continuous Operations	$366.95M
Consolidated Net Income/Loss	$366.95M
Normalized Income after Taxes	$366.95M
EBIT	$532.22M
EBITDA	$880.25M
Weighted-Average Shares Outstanding (Basic)	341.73M
Weighted-Average Shares Outstanding (Diluted)	345.56M
Earnings per Share (EPS) (Basic)	$1.08
Earnings per Share (EPS) (Diluted)	$1.06
Balance Sheet Financials
Current Assets	$1.25B
Property, Plant, and Equipment	$149.85M
Long-Term Assets	$5.89B
Total Assets	$7.14B
Current Liabilities	$1.19B
Long-Term Debt	$1.17B
Long-Term Liabilities	$2.13B
Total Liabilities	$3.33B
Common Equity	$3.81B
Tangible Shareholders Equity	$-1.77B
Shareholders Equity	$3.81B
Common Shares Outstanding	343.44M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$698.90M
Cash Flow from Investing Activities	$-292.41M
Cash Flow from Financial Activities	$-378.49M
Beginning Cash	$85.52M
End Cash	$107.84M
Increase/Decrease in Cash	$22.33M
Stock-Based Compensation	--
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.04
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.24
Debt to Equity Ratio	0.41
Gross Margin	77.77%
Operating Margin	21.62%
EBIT Margin	21.62%
EBITDA Margin	35.75%
Pre-Tax Profit Margin	16.93%
Profit Margin	14.93%
Free Cash Flow	$682.82M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.34
Inventory Turnover	1.39
Receiveable Turnover	4.65
Days Sales in Receivables	78.53
Return on Equity	9.63%
Return on Tangible Equity	-20.77%
Return on Assets	5.14%
Return on Investments	7.36%
Book Value Per Share	$11.10
Free Cash Flow per Share	$1.98
Operating Cash Flow per Share	$2.02

Data from Zacks Investment Research, Inc.